Obtain the data you need to make the most informed decisions by accessing our extensive portfolio of information, analytics, and expertise. Sign in to the product or service center of your choice.
The risks of Brexit, IRP and pricing and pharmaceutical market access
The global pharmaceutical industry continues to face a wide array of fast-moving risks and evolving uncertainties. Pressure on pharmaceutical prices is nothing new—from reputational risks in the United States to access restrictions in Europe—but new challenges are emerging through the highly disruptive Brexit process and increasing risks from International Reference Pricing (IRP).
Please save the date and join the IHS Markit experts on 4th July in Paris, France for the Life Sciences Breakfast briefing, where they will address the following topics: